Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(10%)
Results Posted
71%(5 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
3
30%
Ph phase_2
4
40%
Ph not_applicable
1
10%
Ph phase_3
2
20%

Phase Distribution

3

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
2(20.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(7)
Terminated(2)

Detailed Status

Completed7
Recruiting1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (30.0%)
Phase 24 (40.0%)
Phase 32 (20.0%)
N/A1 (10.0%)

Trials by Status

recruiting110%
completed770%
terminated110%
withdrawn110%

Recent Activity

1 active trials
Showing 5 of 10
recruitingphase_1

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

NCT05025605
completedphase_1

Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV

NCT02579083
completedphase_3

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

NCT04276883
terminatedphase_2

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

NCT05276830
completedphase_3

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

NCT04268303
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05025605Phase 1

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Recruiting
NCT02579083Phase 1

Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV

Completed
NCT04276883Phase 3

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

Completed
NCT05276830Phase 2

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

Terminated
NCT04268303Phase 3

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

Completed
NCT04010305Phase 1

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

Completed
NCT05313386Phase 2

Study of BXCL501 In Agitation Associated With Delirium in ICU Patients

Withdrawn
NCT02908503Not Applicable

Vaginal Film Administration and Placement Study: FLAG

Completed
NCT00941304Phase 2

Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain

Completed
NCT01871285Phase 2

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10